The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Leukemia, Myelomonocytic, Chronic

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Leukemia, Myelomonocytic, Chronic


High impact information on Leukemia, Myelomonocytic, Chronic


Chemical compound and disease context of Leukemia, Myelomonocytic, Chronic


Biological context of Leukemia, Myelomonocytic, Chronic


Anatomical context of Leukemia, Myelomonocytic, Chronic


Gene context of Leukemia, Myelomonocytic, Chronic


Analytical, diagnostic and therapeutic context of Leukemia, Myelomonocytic, Chronic


  1. A role for proapoptotic BID in the DNA-damage response. Zinkel, S.S., Hurov, K.E., Ong, C., Abtahi, F.M., Gross, A., Korsmeyer, S.J. Cell (2005) [Pubmed]
  2. RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. Janssen, J.W., Steenvoorden, A.C., Lyons, J., Anger, B., Böhlke, J.U., Bos, J.L., Seliger, H., Bartram, C.R. Proc. Natl. Acad. Sci. U.S.A. (1987) [Pubmed]
  3. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Raza, A., Qawi, H., Lisak, L., Andric, T., Dar, S., Andrews, C., Venugopal, P., Gezer, S., Gregory, S., Loew, J., Robin, E., Rifkin, S., Hsu, W.T., Huang, R.W. Blood (2000) [Pubmed]
  4. A new subtype of pre-B acute lymphoblastic leukemia with t(5;12)(q31q33;p12), molecularly and cytogenetically distinct from t(5;12) in chronic myelomonocytic leukemia. Wlodarska, I., Aventín, A., Inglés-Esteve, J., Falzetti, D., Criel, A., Cassiman, J.J., Mecucci, C., Van den Berghe, H., Marynen, P. Blood (1997) [Pubmed]
  5. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Stover, E.H., Chen, J., Lee, B.H., Cools, J., McDowell, E., Adelsperger, J., Cullen, D., Coburn, A., Moore, S.A., Okabe, R., Fabbro, D., Manley, P.W., Griffin, J.D., Gilliland, D.G. Blood (2005) [Pubmed]
  6. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Golub, T.R., Barker, G.F., Lovett, M., Gilliland, D.G. Cell (1994) [Pubmed]
  7. Successful treatment with hydroxyurea of ocular involvement in chronic myelomonocytic leukemia. Wolff-Kormann, P.G., Hasenfratz, B.C., Heinrich, B., Kormann, B. N. Engl. J. Med. (1991) [Pubmed]
  8. Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581. Tomasson, M.H., Sternberg, D.W., Williams, I.R., Carroll, M., Cain, D., Aster, J.C., Ilaria, R.L., Van Etten, R.A., Gilliland, D.G. J. Clin. Invest. (2000) [Pubmed]
  9. Interleukin 4 suppresses the spontaneous growth of chronic myelomonocytic leukemia cells. Akashi, K., Shibuya, T., Harada, M., Takamatsu, Y., Uike, N., Eto, T., Niho, Y. J. Clin. Invest. (1991) [Pubmed]
  10. FMS mutations in myelodysplastic, leukemic, and normal subjects. Ridge, S.A., Worwood, M., Oscier, D., Jacobs, A., Padua, R.A. Proc. Natl. Acad. Sci. U.S.A. (1990) [Pubmed]
  11. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Golub, T.R., Barker, G.F., Bohlander, S.K., Hiebert, S.W., Ward, D.C., Bray-Ward, P., Morgan, E., Raimondi, S.C., Rowley, J.D., Gilliland, D.G. Proc. Natl. Acad. Sci. U.S.A. (1995) [Pubmed]
  12. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. Beran, M., Estey, E., O'Brien, S., Cortes, J., Koller, C.A., Giles, F.J., Kornblau, S., Andreeff, M., Vey, N., Pierce, S.R., Hayes, K., Wong, G.C., Keating, M., Kantarjian, H. J. Clin. Oncol. (1999) [Pubmed]
  13. Low-dose cytosine arabinoside in adult chronic myelomonocytic leukemia. Fenaux, P., Jouet, J.P., Bauters, F. J. Clin. Oncol. (1987) [Pubmed]
  14. Protease inhibitor 10 inhibits tumor necrosis factor alpha -induced cell death. Evidence for the formation of intracellular high M(r) protease inhibitor 10-containing complexes. Schleef, R.R., Chuang, T.L. J. Biol. Chem. (2000) [Pubmed]
  15. Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia. Gunby, R.H., Cazzaniga, G., Tassi, E., Le Coutre, P., Pogliani, E., Specchia, G., Biondi, A., Gambacorti-Passerini, C. Haematologica (2003) [Pubmed]
  16. Complete remission of TEL-PDGFRB-induced myeloproliferative disease in mice by receptor tyrosine kinase inhibitor SU11657. Cain, J.A., Grisolano, J.L., Laird, A.D., Tomasson, M.H. Blood (2004) [Pubmed]
  17. Exon trap analysis of a NF1 splice-site mutation in a chronic myelomonocytic leukemia patient. Ludwig, L., Janssen, J.W., Bartram, C.R. Leukemia (1995) [Pubmed]
  18. Novel MLL-CBP fusion transcript in therapy-related chronic myelomonocytic leukemia with a t(11;16)(q23;p13) chromosome translocation. Satake, N., Ishida, Y., Otoh, Y., Hinohara, S., Kobayashi, H., Sakashita, A., Maseki, N., Kaneko, Y. Genes Chromosomes Cancer (1997) [Pubmed]
  19. Prolonged extreme thrombocytosis associated with neurofibromatosis type 1. Hasle, H., Nir, M., Tommerup, N. J. Pediatr. (1997) [Pubmed]
  20. Detection of c-kit point mutation Asp-816 --> Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia. Sotlar, K., Fridrich, C., Mall, A., Jaussi, R., Bültmann, B., Valent, P., Horny, H.P. Leuk. Res. (2002) [Pubmed]
  21. Chronic myelomonocytic leukemia according to FAB classification: analysis of 35 cases. Solal-Celigny, P., Desaint, B., Herrera, A., Chastang, C., Amar, M., Vroclans, M., Brousse, N., Mancilla, F., Renoux, M., Bernard, J.F. Blood (1984) [Pubmed]
  22. Therapy-related myelodysplastic syndromes: FAB classification, bone marrow histology, and immunohistology in the prognostic assessment. Orazi, A., Cattoretti, G., Soligo, D., Luksch, R., Lambertenghi-Deliliers, G. Leukemia (1993) [Pubmed]
  23. Leukapheresis in chronic myelomonocytic leukemia with leukostasis syndrome: elevated serum lactate levels as an early sign of microcirculation failure. Stemmler, J., Wittmann, G.W., Hacker, U., Heinemann, V. Leuk. Lymphoma (2002) [Pubmed]
  24. LRP overexpression in monocytic lineage. Sunnaram, B.L., Gandemer, V., Sebillot, M., Grandgirard, N., Amiot, L., Leray, E., Goasguen, J.E. Leuk. Res. (2003) [Pubmed]
  25. Chronic myelomonocytic leukemia with t(7;11)(p15;p15) and NUP98/HOXA9 fusion. Wong, K.F., So, C.C., Kwong, Y.L. Cancer Genet. Cytogenet. (1999) [Pubmed]
  26. Huntingtin interacting protein 1 Is a clathrin coat binding protein required for differentiation of late spermatogenic progenitors. Rao, D.S., Chang, J.C., Kumar, P.D., Mizukami, I., Smithson, G.M., Bradley, S.V., Parlow, A.F., Ross, T.S. Mol. Cell. Biol. (2001) [Pubmed]
  27. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Bellamy, W.T., Richter, L., Sirjani, D., Roxas, C., Glinsmann-Gibson, B., Frutiger, Y., Grogan, T.M., List, A.F. Blood (2001) [Pubmed]
  28. IL-4 stimulates the growth of chronic myelomonocytic leukemia cells (CMMoL) once leukemic transformation has occurred. Yanagisawa, K., Hatta, N., Watanabe, I., Horiuchi, T., Hasegawa, H., Fujita, S. Leukemia (1995) [Pubmed]
  29. Mast cell growth factor (c-kit ligand) restores growth of multipotent progenitors in myelodysplastic syndrome. Glinsmann-Gibson, B., Spier, C., Baier, M., Taetle, R., Broudy, V.C., List, A.F. Leukemia (1994) [Pubmed]
  30. ETV6 gene rearrangements in hematopoietic malignant disorders. Wlodarska, I., Mecucci, C., Baens, M., Marynen, P., van den Berghe, H. Leuk. Lymphoma (1996) [Pubmed]
  31. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Mittal, P., Saliba, R.M., Giralt, S.A., Shahjahan, M., Cohen, A.I., Karandish, S., Onida, F., Beran, M., Champlin, R.E., de Lima, M. Bone Marrow Transplant. (2004) [Pubmed]
  32. Veno-occlusive disease of the liver associated with chronic myelomonocytic leukemia treated with vincristine and standard doses of cytarabine. Boula, A.M., Mantadakis, E., Xilouri, I.M., Christoforidou, A.V., Foudoulakis, A.M., Samonis, G. Am. J. Hematol. (2005) [Pubmed]
  33. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Kerbauy, D.M., Chyou, F., Gooley, T., Sorror, M.L., Scott, B., Pagel, J.M., Myerson, D., Appelbaum, F.R., Storb, R., Deeg, H.J. Biol. Blood Marrow Transplant. (2005) [Pubmed]
WikiGenes - Universities